A study to evaluate the dose optimization measures and safety of ABBV-383 in subjects with Relapsed or Refractory Multiple Myeloma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504674-38-00

Acronym

M24-108

Enrollment

Registered

2023-07-17

Start date

2023-07-31

Completion date

Unknown

Last updated

2025-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Denmark, France, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026